The FDA has approved a generic daily injectable, the liraglutide injection, for patients aged 10 years and up who have Type 2 diabetes. This injectable, sold under the name Victoza, which is currently in short supply, offers a more affordable solution for those requiring GLP-1 medications. However, patients with particular medical conditions are advised against using the medicine.
CISOs flag gaps in GenAI strategy, skills, and infrastructure
A majority of C-suite leaders believe Generalized Artificial Intelligence (GenAI) is crucial for innovation while committing to further investment, according to NTT DATA. However, 45%
